Skip to main content

Table.1 Baseline characteristics of 67 patients who underwent surgical resection

From: Outcomes of adjunctive surgery for nontuberculous mycobacterial pulmonary disease

Characteristics n = 67
Age years, median (IQR) 57 (50, 65)
Female sex, n (%) 53 (79.1)
BMI kg/m2 (n = 47), median (IQR) 20.1 (18.7, 21.3)
Smoking status, Never/former, n (%) 59 (88.1)/8 (11.9)
Underlying disease
 History of pulmonary TB, n (%) 10 (14.9)
 Lung cancer, n (%) 2 (3)
 Asthma, n (%) 2 (3)
 COPD, n (%) 1 (1.5)
 Other malignancy, n (%) 5 (7.5)
 Diabetes mellitus, n (%) 3 (4.5)
 Charlson comorbidity index, median (IQR) 2 (1, 3)
Causative Mycobacterium species
 MAC, n (%) 39 (58.2)
  M. avium, n (%) 18 (26.9)
  M. intracellulare, n (%) 21 (31.3)
 MABC, n (%) 24 (35.8)
  M. abscessus, n (%) 16 (23.9)
  M. massiliense, n (%) 8 (11.9)
 M. kansasii, n (%) 3 (4.5) 
 M. fortuitum, n (%) 1 (1.5)
Clarithromycin resistance in MABC
  M. abscessus (n = 13), S/IR or R, n (%) 2 (3)/11 (16.4)
  M. massiliense (n = 8), S/IR or R, n (%) 7 (87.5)/1 (12.5)
Preoperative positive NTM culture, n (%) 54 (80.6)
CT pattern
 Non-cavitary nodular bronchiectatic, n (%) 19 (28.4)
 Cavitary nodular bronchiectatic, n (%) 34 (50.7)
 Fibrocavitary, n (%) 14 (20.9)
Disease extent
 Involving a single lobe, n (%) 7 (10.4)
 Involving more than three lobes, n (%) 46 (68.7)
 Bilateral involvement, n (%) 49 (73.1)
 Involving all lobes, n (%) 12 (17.9)
Preoperative PFT
 FEV1/FVC ratio, median (IQR) 76.5 (70, 80.8)
 % predicted FEV1, median (IQR) 94 (83.3, 101.8)
 % predicted FVC, median (IQR) 90 (81, 99)
 % DLCO, median (IQR) 87 (77, 96.5)
Preoperative NTM treatment
 On antibiotics treatment prior to surgery, n (%) 61 (91)
  Guideline-adhering regimens, n (%) 58 (95.1)
  Macrolide-based regimen with intravenous drugs, n (%) 29 (47.5)
  Macrolide-based regimen without intravenous drugs, n (%) 31 (50.8)
  Non-macrolide-based regimen, n (%) 1 (1.6)
 Treatment duration, months, median (IQR) 14 (9, 25)
 No antibiotic treatment before surgery, n (%) 6 (9)
Surgical indication  
 Persistent NTM culture positivity, n (%) 54 (80.6)
 Radiographic aggravation and/or persistent cavity, n (%) 7 (10.4)
 Massive hemoptysis, n (%) 3 (4.5)
 Initiation of therapy, n (%) 1 (1.5)
 Others, n (%) 2 (3)
  1. IQR Interquartile range, BMI body mass index, TB tuberculosis, COPD Chronic obstructive pulmonary disease, MAC Mycobacterium avium complex, MABC Mycobacterium abscessus complex, S susceptible, IR inducible resistance, R resistance, NTM nontuberculous mycobacteria, CT computed tomography, PFT pulmonary function test, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, DLCO diffusing capacity of the lungs for carbon monoxide